Evidence map›Paper›PMID 37416333›Full record

ArticleJournal of radiosurgery and SBRT2022

Association between biologically effective dose and local control after stereotactic body radiotherapy for metastatic sarcoma.

Eashwar Somasundaram, Timothy D Smile, Ahmed Halima, James B Broughman, Chandana A Reddy, Shireen Parsai, Jacob G Scott, Chirag Shah, Timothy Chan, Shauna Campbell and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of radiosurgery and SBRT, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

Eashwar SomasundaramCase Western Reserve University School of Medicine, Cleveland, OH, USA.
Timothy D SmileDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Ahmed HalimaDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
James B BroughmanDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Chandana A ReddyDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Shireen ParsaiDepartment of Radiation Oncology, Ohio Health Riverside Methodist Hospital, Columbus, OH, USA.
Jacob G ScottDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Chirag ShahDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Timothy ChanDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Shauna CampbellDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Lilyana AngelovRose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA.
Peter M AndersonDepartment of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, OH, USA.
Stacy ZahlerDepartment of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, OH, USA.
Matteo TruccoDepartment of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, OH, USA.
Stefanie M ThomasDepartment of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, OH, USA.
Shavaughn JohnsonDepartment of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, OH, USA.
Nathan MeskoDepartment of Orthopedic Surgery, Cleveland Clinic, Cleveland, OH, USA.
Lukas NystromDepartment of Orthopedic Surgery, Cleveland Clinic, Cleveland, OH, USA.
Dale ShepardDepartment of Hematology and Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
George Thomas BuddDepartment of Hematology and Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Peng QiDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Anthony MagnelliDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Erin S MurphyDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Cleveland Clinic · USCase Western Reserve University · USOhioHealth · USSylvester Comprehensive Cancer Center · USUniversity of North Carolina at Chapel Hill · USUniversity School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Stereotactic body radiation therapy (SBRT) is increasingly utilized for patients with recurrent and metastatic sarcoma. SBRT affords the potential to overcome the relative radioresistance of sarcomas through delivery of a focused high biological effective dose (BED) as an alternative to invasive surgery. We report local control outcomes after metastatic sarcoma SBRT based on radiation dose and histology. Methods: From our IRB-approved single-institution registry, all patients treated with SBRT for metastatic sarcoma between 2014 and 2020 were identified. Kaplan-Meier analysis was used to estimate local control and overall survival at 1 and 2 years. A receiver operating characteristic (ROC) curve was generated to determine optimal BED using an α/β ratio of 3. Local control was compared by SBRT dose using the BED cut point and evaluated by histology. Results: Forty-two patients with a total of 138 lesions met inclusion criteria. Median imaging follow up was 7.73 months (range 0.5-35.0). Patients were heavily pre-treated with systemic therapy. Median SBRT prescription was 116.70 Gy BED (range 66.70-419.30). Desmoplastic small round cell tumor, Ewing sarcoma, rhabdomyosarcoma, and small round blue cell sarcomas were classified as radiosensitive ( Conclusion: There is a significant local control benefit for sarcoma SBRT when a BED > 95 Gy is used. Further investigation into the dose-response relationship is warranted to maximize the therapeutic index.

Indexed as

biological effective dosedoselocal controlSarcomaSBRT

Identifiers

PMID37416333
PMCPMC10322177
OpenAlexW3208842440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.